The effect of inhaled corticosteroids (ICS) on airway inflammation in chronic obstructive pulmonary disease (COPD)

A randomized controlled trial over 6 months to determine the effects of fluticasone propionate on lung function symptom scores, airway inflammation and airway structural remodelling in adult subjects with smoking related COPD

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612001111864

Enrollment

Registered

2012-10-17

Start date

2001-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to describe in better detail the airway inflammation and remodelling that we know occurs in COPD and to see what effect inhaled steroid medication has on the inflammation/structural changes and symptoms of the disease over a 6 month period.

Interventions

Inhaled fluticasone propionate versus placebo, 500mcg twice per day for 6 months

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

FEV1/FVC < 70% post bronchodilator and no other major co-morbidities

Exclusion criteria

Major confounding co-morbidities, steroids therapy in last 3 months

Outcome results